Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study.

P, Mitchell; J, Arnold; S, Fraser-Bell; HK, Kang; AA, Chang; J, Tainton; S, Simonyi

doi:10.1136/bmjophth-2022-001224

Public

Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study.

Shared by NobleBlocks on Aug 1, 2023 • 12:00 AM UTC

Authors:

Mitchell P

Arnold J

Fraser-Bell S

Abstract

<h4>Aim</h4>To evaluate effectiveness of dexamethasone intravitreal implant 0.7 mg (DEX) monotherapy in the AUSSIEDEX study non-responder subgroup, defined by diabetic macular oedema (DME) refractory to anti-vascular endothelial growth factor (anti-VEGF) agents.<h4>Methods</h4>This prospective, open...

Subject

Retina

Vision

Inflammation

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!